These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 14648110)

  • 1. Infliximab in two patients with juvenile ankylosing spondylitis.
    Schmeling H; Horneff G
    Rheumatol Int; 2004 May; 24(3):173-6. PubMed ID: 14648110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
    Braun J; Baraliakos X; Brandt J; Listing J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Sieper J
    Rheumatology (Oxford); 2005 May; 44(5):670-6. PubMed ID: 15757965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintained clinical response of infliximab treatment in ankylosing spondylitis: a 6-year long-term study.
    Saougou I; Markatseli TE; Voulgari PV; Drosos AA
    Joint Bone Spine; 2010 Jul; 77(4):325-9. PubMed ID: 20452801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
    Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
    Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
    J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab: in ankylosing spondylitis.
    Robinson DM; Keating GM
    Drugs; 2005; 65(9):1283-91; discussion 1292-4. PubMed ID: 15916451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab.
    Brandt J; Haibel H; Cornely D; Golder W; Gonzalez J; Reddig J; Thriene W; Sieper J; Braun J
    Arthritis Rheum; 2000 Jun; 43(6):1346-52. PubMed ID: 10857793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of refractory inflammatory monoarthritis in ankylosing spondylitis by intraarticular injection of infliximab.
    Schatteman L; Gyselbrecht L; De Clercq L; Mielants H
    J Rheumatol; 2006 Jan; 33(1):82-5. PubMed ID: 16292792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
    Elkayam O; Bashkin A; Mandelboim M; Litinsky I; Comaheshter D; Levartovsky D; Mendelson E; Wigler I; Caspi D; Paran D
    Semin Arthritis Rheum; 2010 Jun; 39(6):442-7. PubMed ID: 19246078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosage adjustment of anti-tumor necrosis factor-α inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice.
    Paccou J; Baclé-Boutry MA; Solau-Gervais E; Bele-Philippe P; Flipo RM
    J Rheumatol; 2012 Jul; 39(7):1418-23. PubMed ID: 22707611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of tumor necrosis factor inhibitor on serum level of HLA-B27 and PDCD-1 in patients with ankylosing spondylitis.
    Chen X; Zhou X; Li X; Tang J; Hu X; Wang J; Xu C
    Cell Biochem Biophys; 2014 Nov; 70(2):1453-7. PubMed ID: 25005770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation.
    de Vries MK; Wolbink GJ; Stapel SO; de Vrieze H; van Denderen JC; Dijkmans BA; Aarden LA; van der Horst-Bruinsma IE
    Ann Rheum Dis; 2007 Sep; 66(9):1252-4. PubMed ID: 17472991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
    Braun J; Baraliakos X; Listing J; Fritz C; Alten R; Burmester G; Krause A; Schewe S; Schneider M; Sörensen H; Zeidler H; Sieper J
    Ann Rheum Dis; 2008 Mar; 67(3):340-5. PubMed ID: 17967831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy and safety of multiple intravenous infusions of infliximab in refractory ankylosing spondylitis patients with axial involvement.
    Rejón E; Giménez MD; Mayordomo L; Rodríguez S; González MP; Marenco JL
    Scand J Rheumatol; 2004; 33(5):323-6. PubMed ID: 15513681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis.
    Baraliakos X; Haibel H; Listing J; Sieper J; Braun J
    Ann Rheum Dis; 2014 Apr; 73(4):710-5. PubMed ID: 23505240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of infliximab treatment on QT intervals in patients with ankylosing spondylitis.
    Senel S; Cobankara V; Taskoylu O; Guclu A; Evrengul H; Kaya MG
    J Investig Med; 2011 Dec; 59(8):1273-5. PubMed ID: 21955979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system.
    Braun J; Baraliakos X; Golder W; Brandt J; Rudwaleit M; Listing J; Bollow M; Sieper J; Van Der Heijde D
    Arthritis Rheum; 2003 Apr; 48(4):1126-36. PubMed ID: 12687557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy.
    Tse SM; Burgos-Vargas R; Laxer RM
    Arthritis Rheum; 2005 Jul; 52(7):2103-8. PubMed ID: 15986366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.
    Braun J; Brandt J; Listing J; Zink A; Alten R; Golder W; Gromnica-Ihle E; Kellner H; Krause A; Schneider M; Sörensen H; Zeidler H; Thriene W; Sieper J
    Lancet; 2002 Apr; 359(9313):1187-93. PubMed ID: 11955536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study.
    Temekonidis TI; Alamanos Y; Nikas SN; Bougias DV; Georgiadis AN; Voulgari PV; Drosos AA
    Ann Rheum Dis; 2003 Dec; 62(12):1218-20. PubMed ID: 14644863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.